Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Z Fan

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Applied Optics|May 1, 1997
Comparison of the exposure characteristics of soft-x-ray film SIOFM-5FW with Kodak 101-05 and Ilford Q-platesP Z Fan, J Z Zhou, Y L Li
Applied Optics|August 25, 2010
Stigmatic grazing-incidence flat-field grating spectrographP Z Fan, Z Q Zhang, J Z Zhou, et al.
Frontiers in Pharmacology|September 13, 2021
The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World StudyD J Ouyang, Q T Chen, M Anwar, et al.
Zhonghua Yi Xue Za Zhi|May 11, 2018
[A multicenter, randomized, controlled, phase Ⅳ clinical study of PEG-rhG-CSF for preventing chemotherapy induced neutropenia in patients with breast cancer]Z F Jiang, F R Xu, J Fan, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|April 23, 2025
[Phase Ⅲ, multicenter, randomized comparative study of LY01005 and Zoladex<sup>®</sup> for patients with premenopausal breast cancer]X Y Shao, Q Y Zhang, Z F Niu, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Applied Optics|May 1, 1997
Comparison of the exposure characteristics of soft-x-ray film SIOFM-5FW with Kodak 101-05 and Ilford Q-platesP Z Fan, J Z Zhou, Y L Li
Applied Optics|August 25, 2010
Stigmatic grazing-incidence flat-field grating spectrographP Z Fan, Z Q Zhang, J Z Zhou, et al.
Frontiers in Pharmacology|September 13, 2021
The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World StudyD J Ouyang, Q T Chen, M Anwar, et al.
Zhonghua Yi Xue Za Zhi|May 11, 2018
[A multicenter, randomized, controlled, phase Ⅳ clinical study of PEG-rhG-CSF for preventing chemotherapy induced neutropenia in patients with breast cancer]Z F Jiang, F R Xu, J Fan, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|April 23, 2025
[Phase Ⅲ, multicenter, randomized comparative study of LY01005 and Zoladex<sup>®</sup> for patients with premenopausal breast cancer]X Y Shao, Q Y Zhang, Z F Niu, et al.
Pageof 1